United Kingdom Archives

News and Trends 7 Dec 2022

Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, has signed a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalized cancer immunotherapy. The agreement focuses on the provision of clinical material for use in Odimma’s oncological neoantigen program. Through the deal, Odimma will gain access to […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Dec 2022

ImaginAb launching clinical trial for renal cancer and malignant melanoma

ImaginAb Inc., which is focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapy (RPT) products, is starting a phase II clinical trial. The trial, PRETZCEL, which will take place at Hull University Teaching Hospitals NHS Trust in the U.K., will investigate ImaginAb’s investigational CD8 ImmunoPET agent in patients with melanoma or […]

December 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

Fallouh Healthcare’s device to give early diagnosis for post-surgery strangulation risk

U.K.-based Fallouh Healthcare is developing a device to monitor cardiac patients after surgery, which is when a condition, called cardiac tamponade, can strike. The company says patients recovering from heart surgery can be at risk from the life-threatening condition that sees fluid build-up around the heart, strangling its ability to beat properly. Fallouh Healthcare, formed […]

December 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Dec 2022

New company Liminatus Pharma Inc to develop three cancer treatments

Clinical-stage biopharma company Liminatus Pharma LLC and Iris Acquisition Corp, a publicly traded special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed Liminatus Pharma, Inc.. The […]

December 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

Bactobio raises £6M to search for new antimicrobials

U.K. biotech company Bactobio Ltd. has closed an oversubscribed £6 million ($7.4 million) bridge financing round. The financing was led by Bridford Group, with support from angel investors Peder Holk Nielsen (former CEO and president of Novozymes) and Hugh Grant (former chairman and CEO of Monsanto). New investors included the founders of the London-based fintech […]

December 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Nov 2022

Touchlight receives new grant to further develop doggybone DNA vaccine platform

UK-based biotechnology company, Touchlight, has received a new grant from the Bill & Melinda Gates Foundation. The company will use the money to further its pre-clinical development of its doggybone DNA vaccine platform. The program aims to build on evidence that Touchlight’s rapid enzymatic doggybone DNA vaccines can produce strong neutralizing antibodies and durable T […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Nov 2022

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

BioPharma Dynamics have expanded their portfolio for the cell and gene therapy market to offer a range of chemically defined T-Cell media, DMSO-free cryopreservation solutions, and recombinant growth factors. Suitable for cell therapy applications at any stage, the portfolio of cell media products include immune cell media, stem cell media, and cell cryopreservation solutions. Supporting applications which […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the partners said they aim to unlock new approaches that not only make disease treatment better, but also present potential cures for patients. Immune-mediated inflammatory diseases […]

November 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Replay receives $1.5M grant for hypoimmunogenic technology platform

Genome writing company Replay has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell, a proprietary hypoimmunogenic technology platform. Replay’s uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (induced pluripotent stem cells) to be made immune silent. […]

November 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Aptamer opens new facilities to meet growing demand for Optimer technology

Aptamer Group developer of Optimer binders that enable development in the life sciences industry has opened new facilities in the UK’s York Science Park. It says this will enable it to meet the growing demand for Optimer technology. Well-known and respected neuroscience researcher, Baroness Susan Greenfield, opened the new 18,000 square-foot site on November 25. […]

November 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 25 Nov 2022

New function of CRISPR gene scissors discovered

For several years, the CRISPR/Cas9 gene scissors have been causing a sensation in science and medicine. Researchers from the Institute of Structural Biology at the University Hospital Bonn (UKB) in Germany and the Medical Faculty of the University of Bonn, in cooperation with the partner University of St Andrews in Scotland and the European Molecular […]

November 25, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy

ImaginAb launching clinical trial for renal cancer and malignant melanoma

Fallouh Healthcare’s device to give early diagnosis for post-surgery strangulation risk

New company Liminatus Pharma Inc to develop three cancer treatments

Bactobio raises £6M to search for new antimicrobials

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Touchlight receives new grant to further develop doggybone DNA vaccine platform

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Replay receives $1.5M grant for hypoimmunogenic technology platform

Aptamer opens new facilities to meet growing demand for Optimer technology

New function of CRISPR gene scissors discovered

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!